Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKrm22 Plc Regulatory News (KRM)

Share Price Information for Krm22 Plc (KRM)

Share Price is delayed by 15 minutes
Get Live Data
32.50    0.00 (0.00%)
Bid:
32.00
Ask:
33.00
Spread: 1.00 (3.125%)
Market Cap: £19.28m
KRM Live PriceLast checked at - London Stock Exchange

Intraday Krm22 Plc Share Chart

Directorate Changes

3 Dec 2019 07:00

RNS Number : 4153V
KRM22 PLC
03 December 2019
 

KRM22 plc

 

("KRM22" or the "Company")

 

Directorate Changes

 

KRM22 plc, (AIM: KRM) the technology and software investment company that focuses on risk management for capital markets, today announces the appointment of Steve Sparke as a Non-Executive Director of the Company. Mr Sparke will replace Matt Reed, Independent Non-Executive Director, who notified the Board of his intention to step down from the Board with immediate effect after being with the Company since its IPO in early 2018. Mr Reed is stepping down to focus on other business commitments.

 

Steve has over 30 years' experience in the Exchange Traded Derivatives ("ETD") and Commodity industry with extensive board-level experience for global ETD and Commodities organisations. He has a deep understanding of application of IT for strategic advantage and extensive expertise in optimising operational functions included technology, legal, risk and compliance.

 

Steve was recently COO of Marex Spectron where he was responsible for the firm's operating environment including operations, risk, compliance and HR. During his time at Marex, he expanded the global footprint of the organisation with new regulated entities and offices opened in New York and Hong Kong, boosted the firm's presence in Singapore and transformed the firm's operating model, facilitating growth to become Europe's largest independent commodity broker. He directed the integration of multiple businesses, including the high profile Spectron acquisition. Prior to joining Marex Spectron, he was Managing Director and Global Head of Exchange Traded Derivatives at UBS from 1994 to 2006 where he launched and led the bank's ETD Clearing and Execution business. Steve headed the Short Term Interest Rates business at SBC London Branch from 1987 to 1994.

 

Steve is a currently non-executive Chairman of FIA European Advisory Board and has held various board positions at FIA Washington and NYSE Euronext LIFFE (now ICE Europe). Steve was also non-executive director of AIM listed PATS Systems, a provider of high performance electronic trading and exchange systems for 5 years between 2006 and 2011, during which time he helped re-establish the firms growth trajectory after an extended period of declining market share.

 

With the resignation of Matt and the appointment of Steve, the Board remains comprised of four Independent Non-Executive Directors and the two Executive Directors. In addition to his role as a Non-Executive Director, Steve will replace Matt as Audit Committee Chairman.

 

Keith Todd, Executive Chairman commented:

 

"All the team would like to thank Matt for his valuable contributions since KRM22's IPO and we wish him well for the future. We are delighted to welcome Steve to the KRM22 Board. Steve brings deep industry knowledge and expertise of capital markets and will be a real asset to the Company."

 

 

The following information is disclosed in relation to Stephen Howard Sparke, age 61, pursuant to Schedule Two paragraph (g) and Rule 17 of the AIM Rules for Companies:

 

Current Directorships / Partnerships:

 

Futures Industry Association - Washington

John S Mews RTM Company Limited

Mzuzu Limited

Sparkeworld Limited

 

Previous Directorships / Partnerships (held in the past five years)

 

Nanolytics Capital Advisors Limited

Spectron Commodities Limited

Spectron Oil Limited

Spectron Services Limited

 

 

Mr Sparke currently holds 189,903 ordinary shares in the Company, representing 0.9 per cent. of the issued share capital of the Company. 

 

There is no further information to be disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies.

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

For further information please contact:

 

KRM22 plc InvestorRelations@krm22.com

Keith Todd CBE, Executive Chairman and CEO

Kim Suter, CFO

 

finnCap Ltd (Nominated Adviser and Sole Broker) +44 (0)20 7220 0500

Carl Holmes / Matthew Radley

 

About KRM22 plc

KRM22 is a closed-ended investment company which listed on AIM on 30 April 2018. The Company has been established with the objective of creating value for its investors through the investment in, and subsequent growth and development of, target companies in the technology and software sector, with a focus on risk management in capital markets.

 

Through its investments and the Global Risk Platform, KRM22 helps capital market companies reduce the cost and complexity of risk management. The Global Risk Platform provides applications to help address firms' regulatory, market, technology and operations risk challenges and to manage their entire enterprise risk profile.

 

Capital markets companies' partner with KRM22 to optimize risk management systems and processes, improving profitability and expanding opportunities to increase portfolio returns by leveraging risk as alpha.

 

KRM22 PLC is listed on AIM and the Group is headquartered in London, with offices in several of the world's major financial centres.

 

See more about KRM22 at KRM22.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAUGGMGPUPBPGP
Date   Source Headline
26th May 20263:24 pmRNSHolding(s) in Company
26th May 20262:25 pmRNSHolding(s) in Company
22nd May 20267:00 amRNSDirector Dealings
20th May 202611:19 amRNSDirector Dealings
20th May 20267:00 amRNSNotice of AGM and Posting of Annual Report
13th May 20267:00 amRNSFinal Results
29th Jan 20267:00 amRNSTrading Update
7th Jan 20267:00 amRNSAppointment of Director
20th Nov 20254:12 pmRNSTR-1
11th Nov 20257:00 amRNSIssue of Equity
10th Nov 20259:28 amRNSHolding(s) in Company
5th Nov 20251:05 pmRNSResult of GM
15th Oct 20257:00 amRNSResult of Placing
14th Oct 20254:50 pmRNSProposed Placing and Subscription
17th Sep 20257:00 amRNSInterim Results
7th Aug 20257:00 amRNSTrading Update
21st Jul 20257:00 amRNSIssue of Equity
27th Jun 20252:10 pmRNSResult of AGM
6th Jun 20257:00 amRNSDirector Dealing
2nd Jun 20257:00 amRNSIssue of Restricted Stock Units
30th May 20257:00 amRNSNotice of AGM and Posting of Annual Report
21st May 20257:00 amRNSDirector Dealing
19th May 20257:00 amRNSFinal Results
29th Apr 20257:00 amRNSFacility Amendment
7th Apr 20257:00 amRNSNew Customer Contracts
1st Apr 20257:00 amRNSFacility Amendment
18th Mar 20257:00 amRNSIssue of Equity
4th Mar 20257:00 amRNSNew Customer Contract
13th Feb 20255:00 pmRNSDirector Dealing
22nd Jan 20257:00 amRNSTrading Update
10th Jan 20257:00 amRNSIssue of Equity
23rd Dec 20247:00 amRNSLoan Facility Amendment
15th Oct 20247:00 amRNSIssue of Equity
25th Sep 20247:00 amRNSInterim Results
3rd Sep 20247:00 amRNSChange of Registered Office
29th Aug 20247:00 amRNSNew Customer Contract
22nd Aug 202410:00 amRNSGrant of Options and Director/PDMR Shareholding
19th Aug 20247:00 amRNSIssue of Equity
18th Jul 20247:00 amRNSHalf Year Trading Update
21st Jun 202412:49 pmRNSResult of AGM
29th May 20247:00 amRNSNotice of AGM and Posting of Annual Report
22nd May 20247:00 amRNSFinal Results
16th Apr 20247:00 amRNSDirector Dealings
15th Apr 20247:00 amRNSNew Customer Contract
10th Apr 20247:00 amRNSIssue of Equity
7th Mar 20247:00 amRNSBoard Changes
21st Feb 20247:00 amRNSTrading Update
1st Dec 20237:00 amRNSIssue of Restricted Stock Units
26th Sep 20237:00 amRNSInterim Results
27th Jul 202311:48 amRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.